Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Epic, Avera Ink Deal to Use Liquid Biopsy Platform in Clinical Studies

Epic, Avera Ink Deal to Use Liquid Biopsy Platform in Clinical Studies

Jan 28, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company's circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Dec
02
Featured Webinar

PIK3CA Mutations in Advanced Breast Cancer: The Vital Role of Tissue and Plasma Companion Diagnostics

Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.

Dec
15
Featured Webinar

Case Study: Deployment of High-Throughput SARS-CoV-2 Testing at UC Davis

Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.

What's Popular?

In Cancer

  1. Grail Inks Deal With UK National Health Service to Offer Cancer Screening Blood Test in 2021

  2. European Consortium Seeks to Develop Liquid Biopsy Test for Prostate, Testicular Cancer

    Premium

  3. Illumina, PierianDx Expand Partnership on Cancer Panel Test Reporting

  4. Genetron Health, Wuxi Government Form Joint Venture for Liver Cancer Screening Test

  5. BTIG Initiates Coverage of Oncocyte With Buy Rating

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.